Guggenheim Starts Arcutis Biotherapeutics Inc. (ARQT) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cowen Starts Arcutis Biotherapeutics Inc. (ARQT) at Outperform
February 25, 2020 5:45 AM ESTCowen analyst Ken Cacciatore initiates coverage on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) with a Outperform rating and a price target of $55.00.
For an analyst ratings summary and ratings history on Arcutis Biotherapeutics Inc.... More
